Change in Siegfried’s Executive Committee

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, announces a change in its Executive Committee.

Peter Freisler will join Siegfried as Chief Business Officer and become a member of the Executive Committee, effective August 1, 2025. He succeeds Marianne Späne who has decided to step down from the Executive Committee to focus on non-executive roles.

Peter joins from Evonik, where he held several senior leadership roles over the past decade, most recently serving as Global Vice President Sales and Services for the Health Care business line. He holds an MBA from the Justus-Liebig-Universität, Giessen (Germany), and a Master of Arts in Economics from the University of Milwaukee-Wisconsin (USA).

Marianne Späne joined Siegfried in 2004 and was appointed to the Executive Committee in 2010. She played a pivotal role in Siegfried’s growth journey and strategic development. She will step down from the Executive Committee on July 31, 2025, and will support Peter Freisler during a transition phase until the end of the year. As of January 1, 2026, Marianne Späne is set to join the Board of Directors of DINAMIQS, a Siegfried company specialized in viral vector design and manufacturing.

Marcel Imwinkelried, Chief Executive Officer of Siegfried: “With his extensive experience in business development across regions and markets, Peter Freisler will hit the ground running, driving further growth and accelerating the execution of our go-to-market strategy as part of EVOLVE+. Marianne Späne has been an outstanding colleague whose contributions have played a significant role in Siegfried’s success over the past decades. On behalf of the entire Executive Committee, I extend our heartfelt thanks for her exceptional work and dedication. We are very pleased that Marianne will remain connected to Siegfried by joining the Board of DINAMIQS. Her deep expertise and longstanding experience in the CDMO industry will be a tremendous asset as DINAMIQS enters an exciting growth phase.”

About Siegfried
The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2024, the company achieved sales of CHF 1.295 billion and employed on 31.12.2024 more than 3,800 employees at thirteen sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary Statements Regarding Forward-Looking Statements
This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.